Laurence Zitvogel MD, PhD

Pr L. Zitvogel, MD (clinical oncology), PhD (tumor immunology), PU-PH Faculty Paris Sud, University Paris XI (Clinical Biology), graduated in Medical Oncology from the School of Medicine of the University of Paris in 1992. She started her scientific career when she was at the University of Pittsburgh in the USA in Michael Lotze’s laboratory. She became Research Director at the Institute of National Sante at Research Medical U1015, in a laboratory located at Institute Gustave Roussy, a large cancer Center in Villejuif/France, and the Head of the Center for Clinical Investigations CICBT 507 for vaccine developments at Villejuif.

Her expertise is mainly in dendritic cell and innate effector biology and relevance during tumor development as well as exosome-based vaccine designs. She pioneered the concept of immunogenic cell death and showed that chemotherapy, radiotherapy, and inhibitors of tyrosine kinase mediate their tumoricidal activity, at least partly through the immune system. She is currently working on the mode of action of immune checkpoint blockers.